Analysis Tools|
Allele Symbol Allele Name Allele ID |
Tg(Col1a2-cre/ERT,-ALPP)7Cpd transgene insertion 7, Christopher P Denton MGI:3785760 |
||||||||||||||||||||
| Summary |
4 genotypes
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• bleomycin-treated mice do not exhibit increased dermal thickness and collagen production unlike in similarly treated wild-type mice
|
|
• bleomycin-treated mice do not exhibit increased dermal thickness and collagen production unlike in similarly treated wild-type mice
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
 |
• focal areas of prostate adenocarcinomas are seen by 17 weeks of age in tamoxifen treated mice and these areas of adenocarcinoma expand throughout the life of mutants
• prostates exhibit no regression acutely after castration, indicating castrate-resistant prostate cancer
• administration of Sabutoclax (Bl-97C1), a pan-active Bcl2 protein family antagonist, mediates apoptosis in castrate-resistant prostate cancer cells of 36-week old mutant mice and reduces tumor size, however it has little apoptotic effect on benign prostate tissue
|
|
|
• tamoxifen treated mice develop prostatic intraepithelial neoplasia (PIN) lesions in the prostate by 17 weeks of age, throughout each of the anterior and dorsolateral lobes with 100% penetrance
|
|
|
• focal areas of prostate adenocarcinomas are seen by 17 weeks of age in tamoxifen treated mice and these areas of adenocarcinoma expand throughout the life of mutants
• prostates exhibit no regression acutely after castration, indicating castrate-resistant prostate cancer
• administration of Sabutoclax (Bl-97C1), a pan-active Bcl2 protein family antagonist, mediates apoptosis in castrate-resistant prostate cancer cells of 36-week old mutant mice and reduces tumor size, however it has little apoptotic effect on benign prostate tissue
|
|
|
• tamoxifen treated mice develop prostatic intraepithelial neoplasia (PIN) lesions in the prostate by 17 weeks of age, throughout each of the anterior and dorsolateral lobes with 100% penetrance
|
|
|
• focal areas of prostate adenocarcinomas are seen by 17 weeks of age in tamoxifen treated mice and these areas of adenocarcinoma expand throughout the life of mutants
• prostates exhibit no regression acutely after castration, indicating castrate-resistant prostate cancer
• administration of Sabutoclax (Bl-97C1), a pan-active Bcl2 protein family antagonist, mediates apoptosis in castrate-resistant prostate cancer cells of 36-week old mutant mice and reduces tumor size, however it has little apoptotic effect on benign prostate tissue
|
|
|
• tamoxifen treated mice develop prostatic intraepithelial neoplasia (PIN) lesions in the prostate by 17 weeks of age, throughout each of the anterior and dorsolateral lobes with 100% penetrance
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
| prostate cancer | DOID:10283 |
OMIM:176807 OMIM:300147 OMIM:300704 OMIM:601518 OMIM:602759 OMIM:608656 OMIM:608658 OMIM:609299 OMIM:609558 OMIM:610321 OMIM:610997 OMIM:611100 OMIM:611868 OMIM:611928 OMIM:611955 OMIM:611958 OMIM:611959 |
J:204736 | |
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• at 5 months after tamoxifen injections
|
|
• in tamoxifen-treated mice the walls of small arteries in the lungs, kidneys, and adrenal glands are thickened compared to oil-treated controls
• thickened vessels in the lungs show hypertrophy of the smooth muscle layers
|
|
• in tamoxifen-treated mice the walls of small arteries in the kidneys are thickened compared to oil-treated controls
|
|
• in tamoxifen-treated mice the walls of small arteries in the lungs are thickened compared to oil-treated controls
• thickened vessels in the lungs show hypertrophy of the smooth muscle layers
|
|
• seen in thickened small arteries in the lungs of tamoxifen-treated mice
|
|
• increased expression of Vwf in lung vessels of tamoxifen-treated mice suggestive of endothelial cell damage and similar to what is seen in human scleroderma patients
|
|
• in tamoxifen-treated mice the walls of small arteries in the kidneys are thickened compared to oil-treated controls
|
|
• increase in type I collagen deposition in the interstitium of tamoxifen-treated mice
|
|
• in mice, injected with tamoxifen for 5 consecutive days starting at 2 weeks of age, at 5 months of age compared to control littermates
|
|
• in tamoxifen-treated mice the walls of small arteries in the lungs are thickened compared to oil-treated controls
• thickened vessels in the lungs show hypertrophy of the smooth muscle layers
|
|
• seen in thickened small arteries in the lungs of tamoxifen-treated mice
|
|
• at 5 months after tamoxifen injections
|
|
• loss of hair on the back, head, chest, and sides and around the ears and nose in mice injected with tamoxifen for 5 consecutive days starting at 2 weeks of age
|
|
• tamoxifen-treated mice show progressive dermal fibrosis beginning by 1 month post injection
• a 2.3-fold in total collagen and disorganized collagen fibrils with increased variability in the size and shape of fibrils are seen in the skin of tamoxifen-treated mice
|
|
• dramatic increase in thickness at 5 months after tamoxifen injections
|
|
• at 5 months after tamoxifen injections
|
|
• increase in skin fragility at 5 months after tamoxifen injections
|
|
• skin feels thicker and rougher in tamoxifen treated mice compared to littermate controls
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
| systemic scleroderma | DOID:418 |
OMIM:181750 |
J:134135 | |
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• tamoxifen treated lung fibroblasts treated with an apoptotic stimulus exhibit a 4 fold increase in apoptosis as compared to controls
|
|
• stimulated tamoxifen treated lung fibroblasts fail to proliferate as compared to controls
|
|
• administration of bleomycin (to induce pulmonary fibrosis) to tamoxifen treated mice results in less extensive fibrosis and more diffuse fibrotic lesions affecting larger areas of lungs as compared to controls
|
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO) |
||
|
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support. |
last database update 11/12/2024 MGI 6.24 |
|
|
|
||
